Haya Therapeutics, a biotech firm pioneering precision RNA‑guided therapeutics, has closed a $65 million Series A round led by Sofinnova Partners and Earlybird Venture Capital, according to the company.
The company said that the funding will advance clinical development of its lead long non‑coding RNA (lncRNA) candidate HTX‑001 for heart failure, targeting non‑obstructive hypertrophic cardiomyopathy, and support expansion of its regulatory genome platform into conditions including pulmonary fibrosis, obesity, and age‑related chronic diseases.
Haya Therapeutics claimed that its proprietary platform combines multimodal functional genomics with machine learning to map the “dark genome” and identify pathogenic cell states driven by regulatory RNAs.
Funding participants also include Eli Lilly and Company, ATHOS, +ND Capital, Alexandria Venture Investments, LifeLink Ventures, Apollo Health Ventures, Longview Ventures, 4see Ventures, BERNINA Bioinvest and Schroders Capital.
Haya said that the fresh capital will enable it to initiate clinical trials for HTX‑001 and to expand its pipeline of RNA‑guided medicines, with a view to reprogramming disease‑driving cell states into healthy ones.
This investment underscores growing support for precision RNA therapeutics targeting the regulatory genome and positions Haya to accelerate development of disease‑modifying treatments in chronic and age‑related conditions.
